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Abstract 
Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free 
survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be 
considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being 
administered continuously for a long time period. 
Case report: we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, 
doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone. 
Conclusions: GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various 
chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients. 
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Introduction 
Very few cytotoxic agents have anti-tumour activity in patients 
with advanced soft-tissue sarcomas (STS) resistant to 
ifosfamide and anthracyclines. However, Gemcitabine (GCB) 
has been reported to have a 20% response rate in persistent or 
recurrent uterine leiomyosarcomas (LMS) [1]. Its preferred use 
is in combination with docetaxel as it has high activity (53% RR) 
when used in this regimen in both treated and untreated 
patients with LMS [2], and due to its higher efficacy in 
unselected STS compared to GCB alone [3]. 
We report a clinical case of a woman with advanced high-grade 
uterine leiomyosarcoma refractory to ifosfamide, doxorubicin 
and trabectedin, who experienced a sustained and progressive 
response to GCB alone. 
 
 
 
 
Figure 1a–c.   
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Figure 2a–c. 
Case report 
A 49-year-old female patient, with no relevant co-morbidities, 
underwent a hysterectomy with bilateral ovariectomy in 1999 for 
a high-grade uterine LMS. 
On May 2001, because of lung metastases, the patient received 
six cycles of ifosfamide 9 g/m
2 and epidoxorubicin 90 mg/m
2 
with further tumour progression. 
 
 
 
 
Between November 2001 and November 2003, she underwent 
multiple lung wedge resections and two spleno-
pancreasectomies for LMS metastases. 
Between February and June 2004, because of systemic (lung, 
mediastinal nodes and chest wall) disease progression, the 
patient received five cycles of chemotherapy with docetaxel 75 
mg/m
2 and GCB 1000 mg/m
2. Despite a partial tumour  
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Figure 3a–c. 
 
response (RECIST criteria) lasting for six months, this treatment 
was burdened by high toxicity, such as G4 neutropenia that 
required granulocyte colony-stimulating factor (G-CSF) support, 
G3 fatigue and G2 neurotoxicity. Due to disease progression, 
the patient was started on docetaxel plus GCB in February 
2005, leading to disease stabilization. However, the treatment 
was discontinued due to relevant side effects, thus leading to 
tumour progression within four months. The patient was   
 
 
 
 
sequentially treated with high-dose (12 g/m
2) ifosfamide, 
trabectedin and etoposide, but with further progression. 
In February 2007, the patient suffered from chest pain (Figure 
1a), cough and dyspnea; a bi-weekly 1000 mg/m
2 GCB 
administration was started. Within four weeks of the start of 
treatment the patient obtained complete symptom control, and a 
subsequent CT scan showed tumour regression. A sustained
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and progressive tumour response was demonstrated by 
subsequent CT scans (Figures 1–3), with an overall tumour 
response lasting more than nine months. At present, the patient 
is still asymptomatic and the treatment is still ongoing. 
 
Discussion 
Anti-tumour activity has been observed with the GCB and 
docetaxel combination in patients with advanced sarcoma, 
especially LMS. Although feasible, this regimen appeared to be 
burdened by relevant toxicity, with >20% of patients 
experiencing grade 3 and 4 neutropenia (despite G-CSF as 
primary neutropenia prophylaxis), thrombocytopenia and fatigue 
[2–5]. Mono-therapy with GCB has previously demonstrated 
activity in LMS [1,5]. 
Despite the fact that docetaxel-GCB combination has shown a 
more favourable effect on disease-free survival and overall
survival than GCB alone in patients with unselected STS [3], the 
mono-therapy should be a preferable option due to its lower 
toxicity profile and the possibility for it to be administered 
continuously for a long-time period. 
In our report, GCB attained a sustained and progressive tumour 
response in a patient with advanced uterine LMS refractory to 
many chemotherapic agents, including ifosfamide, anthracycline 
and trabectedin. 
While docetaxel-GCB administration had to be discontinued 
because of toxicity, GCB mono-chemotherapy was very well 
tolerated and resulted in full symptom control. 
The case presented here underlines the value of mono-
chemotherapy for the management of advanced LMS. Indeed, 
gemcitabine when given as a single agent can obtain long-
lasting tumour control in heavily pre-treated patients with uterine 
LMS and should be considered as a possible option for this 
subset of patients. 
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